Glucagonoma: Difference between revisions

	Glucagonoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Glucagonoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Glucagonoma On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Glucagonoma All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Glucagonoma
CDC on Glucagonoma
Glucagonoma in the news
Blogs on Glucagonoma
Directions to Hospitals Treating Glucagonoma
Risk calculators and risk factors for Glucagonoma

VisualWikitext

Latest revision as of 01:48, 27 November 2017

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2], Mohammed Abdelwahed M.D [3]

Synonyms and keywords: Alpha cell adenoma, Alpha cell tumor

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Treatment

Case Studies

Case#1

Template:Epithelial neoplasms

Template:WikiDoc Sources

@@ Line 1: / Line 1: @@
+__NOTOC__
 '''For patient information click [[{{PAGENAME}} (patient information)|here]]'''
+{{Glucagonoma}}
+{{CMG}}; {{AE}} {{PSD}}, {{MAD}}
-{{Infobox_Disease |
+{{SK}} Alpha cell adenoma, Alpha cell tumor
-  Name           = Glucagonoma |
+==[[Glucagonoma overview|Overview]]==
-  Image          = |
-  Caption        = |
-  DiseasesDB     = 5257 |
-  ICD10          = {{ICD10|C|25|4|c|15}} |
-  ICD9           = {{ICD9|157.4}}, {{ICD9|211.7}} |
-  ICDO           = 8152 |
-  OMIM           = |
-  MedlinePlus    = |
-  MeshID         = D005935 |
-}}
-{{SI}}
-{{CMG}}
-{{EH}}
+==[[Glucagonoma historical perspective|Historical Perspective]]==
-==Overview==
+==[[Glucagonoma pathophysiology|Pathophysiology]]==
-A '''glucagonoma''' is a rare [[tumor]] of the [[alpha cell]]s of the [[pancreas]] that results in up to a 1000-fold overproduction of the [[hormone]] [[glucagon]]. Alpha cell tumors are commonly associated with glucagonoma syndrome, though similar symptoms are present in cases of pseudoglucagonoma syndrome in the absence of a glucagon-secreting tumor.
-== History ==
+==[[Glucagonoma causes|Causes]]==
-Fewer than 250 cases of glucagonoma have been described in the literature since their first description by Becker in 1942. Because of its rarity (fewer than one in 20 million worldwide), long-term survival rates are as yet unknown.
-== Symptoms ==
+==[[Glucagonoma differential diagnosis|Differentiating Glucagonoma from other Diseases]]==
-The primary [[physiology|physiological]] effect of glucagonoma is an overproduction of the [[peptide]] hormone [[glucagon]], which enhances [[blood glucose]] levels through the activation of [[catabolism|catabolic]] processes including [[gluconeogenesis]] and [[lipolysis]]. Gluconeogenesis produces [[glucose]] from [[protein]] and [[amino acid]] materials; lipolysis is the breakdown of [[adipose tissue|fat]]. The net result is hyperglucagonemia, decreased blood levels of [[amino acid]]s (hypoaminoacidemia), [[anemia]], [[diarrhea]], and weight loss of 5-15 [[kilogram|kg]].
-[[Necrolytic migratory erythema]] (NME) is a classical symptom observed in patients with glucagonoma and is present in 80% of cases. Associated NME is characterized by the spread of erythematous blisters and swelling across areas subject to greater friction and pressure, including the lower [[abdomen]], [[buttock]]s, [[perineum]], and [[groin]].
+==[[Glucagonoma epidemiology and demographics|Epidemiology and Demographics]]==
-[[Diabetes mellitus]] also frequently results from the [[insulin]] and [[glucagon]] imbalance that occurs in glucagonoma.<ref>{{cite journal |author=Koike N, Hatori T, Imaizumi T, ''et al'' |title=Malignant glucagonoma of the pancreas diagnoses through anemia and diabetes mellitus |journal=Journal of hepato-biliary-pancreatic surgery |volume=10 |issue=1 |pages=101-5 |year=2003 |pmid=12918465 |doi=}}</ref> Diabetes mellitus is present in 80-90% of cases of glucagonoma, and is exacerbated by preexisting [[insulin resistance]].
+==[[Glucagonoma risk factors|Risk Factors]]==
-== Diagnosis ==
+==[[Glucagonoma screening|Screening]]==
-A [[blood serum]] glucagon concentration of 1000 pg/mL or greater is indicative of glucagonoma (the normal range is 50-200 pg/mL).
-Blood tests may also reveal abnormally low concentrations of amino acids, [[zinc]], and [[essential fatty acid]]s, which are thought to play a role in the development of NME. Skin [[biopsy|biopsies]] may also be taken to confirm the presence of NME.
+==[[Glucagonoma natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
-A [[complete blood count|CBC]] can uncover anemia, which is an abnormally low level of [[hemoglobin]].
+==Diagnosis==
+[[Glucagonoma staging|Staging]] | [[Glucagonoma history and symptoms|History and Symptoms]] | [[Glucagonoma physical examination|Physical Examination]] | [[Glucagonoma laboratory tests|Laboratory Findings]] | [[Glucagonoma chest x ray|Chest X Ray]] | [[Glucagonoma CT|CT]] | [[Glucagonoma MRI|MRI]] | [[Glucagonoma ultrasound|Ultrasound]] | [[Glucagonoma other imaging findings|Other Imaging Findings]] | [[Glucagonoma other diagnostic studies|Other Diagnostic Studies]]
-The tumor itself may be localized by any number of radiographic modalities, including [[angiography]], [[computed tomography|CT]], [[magnetic resonance imaging|MRI]], [[positron emission tomography|PET]], and [[endoscopic ultrasound]]. [[Laparotomy]] is useful for obtaining [[histology|histologic]] samples for analysis and confirmation of the glucagonoma.
+==Treatment==
+[[Glucagonoma medical therapy|Medical Therapy]] | [[Glucagonoma surgery|Surgery]] | [[Glucagonoma primary prevention|Primary Prevention]] | [[Glucagonoma secondary prevention|Secondary Prevention]] | [[Glucagonoma cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Glucagonoma future or investigational therapies|Future or Investigational Therapies]]
-== Treatment ==
+==Case Studies==
-Heightened glucagon secretion can be treated with the administration of [[Somatostatin|octreotide, a somatostatin analog]], which inhibits the release of glucagon.<ref>{{cite journal |author=Moattari AR, Cho K, Vinik AI |title=Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: dissociation of responses |journal=Surgery |volume=108 |issue=3 |pages=581-7 |year=1990 |pmid=2168587 |doi=}}</ref> [[Doxorubicin]] and [[streptozotocin]] have also been used successfully to selectively damage alpha cells of the pancreatic islets. These do not destroy the tumor, but help to minimize progression of symptoms.
+[[Glucagonoma case study one|Case#1]]
-The only curative therapy for glucagonoma is [[surgery|surgical]] resection, where the tumor is removed. Resection has been known to reverse symptoms in some patients.
+{{Epithelial neoplasms}}
-== References ==
+[[Category:Disease]]
-{{reflist|2}}
-{{Epithelial neoplasms}}
 [[Category:Types of cancer]]
 [[Category:Oncology]]
-[[Category:Mature chapter]]
+[[Category:Endocrinology]]
-{{SIB}}
-[[de:Glucagonom]]
 {{WikiDoc Help Menu}}
 {{WikiDoc Sources}}
+ [[Category:Up-To-Date]]
+[[Category:Oncology]]
+[[Category:Medicine]]
+[[Category:Gastroenterology]]
+[[Category:Surgery]]

Glucagonoma: Difference between revisions

Latest revision as of 01:48, 27 November 2017

Diagnosis

Treatment

Case Studies

Navigation menu